References
- U.S. Food and Drug Administration [internet]. Humira® prescribing information 2018 [cited 2018 Nov 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf
- European Medicines Agency [internet]. Humira® summary of product characteristics 2018 [cited 2018 Nov 27]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–417.
- Holzmann J, Balser S, Windisch J. Totality of the evidence at work: the first U.S. biosimilar. Expert Opin Biol Ther. 2016;16(2):137–142.
- Schiestl M, Roesli C. Development and analytical characterization of GP2017, a proposed adalimumab biosimilar. Am J Gastroenterol. 2016;111(S289):Abstract628.
- Kronthaler U, Fritsch C, Hainzl O, et al. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opin Biol Ther. 2018;18(8):921–930.
- von Richter O, Lemke L, Haliduola H, et al. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opin Biol Ther. 2019;1–9.
- Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
- Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–926.
- Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–1955.
- Park KR, Chung H, Yang SM, et al. A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers. Expert Opin Investig Drugs. 2017;26(5):619–624.
- Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672–678.
- Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526–533.
- European Medicines Agency [internet]. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 2014 [cited 2019 Feb 03]. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
- U.S. Food and Drug Administration [internet]. Scientific considerations in demonstrating biosimilarity to a reference product 2015 [cited 2019 Feb 03]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf
- U.S. Food and Drug Administration [internet]. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product 2016 [cited 2019 Feb 03]. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf
- Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis. 2013;5(5):561–574.
- Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478.
- Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009;60(8):2541–2542.
- Romero-Cara P, Torres-Moreno D, Pedregosa J, et al. A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF. Int J Med Sci. 2018;15(1):10–15.
- Benucci M, Damiani A, Li Gobbi F, et al. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biologics. 2018;12:37–41.